Amylin had completed the submission of its rolling Biologics License Application (:BLA) for metreleptin in April 2012. Amylin is looking to get metreleptin approved for the treatment of diabetes ...

Amycretin led to a 1.8 reduction in HbA1c levels in the Phase II type 2 diabetes trial.

NEW YORK (AP) — Billionaire investor Carl Icahn demanded Wednesday that Amylin Pharmaceuticals Inc. allow him and other shareholders to nominate candidates to the diabetes drugmaker's board in light ...

Amylin shares skyrocketed this morning, climbing as high as 47%, after the biotech company reportedly rejected a takeover bid from Bristol-Myers Squibb. Bristol-Myers offered to buy Amylin at $22 a ...

Amylin director Karin Eastham has, in essence, called Eastbourne Capital board candidate M. Kathleen Behrens a liar (or at least an amnesiac). On May 11, Behrens had written to Amylin decrying the ...

By Mariam Sunny and Mrinalika Roy (Reuters) -Novo Nordisk reported promising mid-stage results for its experimental obesity ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. As drugmakers rush to scrounge up new contenders in the ...

SAN DIEGO, May 16, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) ("Amylin" or "the Company") today announced that it has filed a lawsuit against Eli Lilly and Company (NYSE: LLY) ...

Amylin said it will hire 365 sales reps to make up for Eli Lilly’s departure from commercial activities, once the firm takes full control of the exenatide diabetes franchise this month. Amylin is ...

Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction Changes Will Result in Over $80 Million Reduction in 2009 Cash Expenditures SAN DIEGO, Nov. 10 -- Amylin ...

Amylin Pharmaceuticals Inc. suffered a setback Wednesday when the Food and Drug Administration said it wouldn’t approve the company’s experimental diabetes drug without additional information. The San ...